Anatomical Resections Improve Disease-free Survival in Patients with KRAS -mutated Colorectal Liver Metastases

Annals of Surgery

Volumn 266, Issue 4, 2017, Pages 641-649

  Margonis, Georgios A ^a   Buettner, Stefan ^a   Andreatos, Nikolaos ^a   Sasaki, Kazunari ^a   Ijzermans, Jan N M ^b   Van Vugt, Jeroen L A ^b   Pawlik, Timothy M ^c   Choti, Michael A ^d   Cameron, John L ^a   He, Jin ^a   Wolfgang, Christopher L ^a   Weiss, Matthew J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

anatomical resection; colorectal liver metastases; disease free survival; KRAS status

Indexed keywords

ANTINEOPLASTIC AGENT; K RAS PROTEIN; KRAS PROTEIN, HUMAN; PROTEIN P21; TUMOR MARKER;

ARTICLE; BILE LEAKAGE; BISEGMENTECTOMY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; COHORT ANALYSIS; COLORECTAL LIVER METASTASIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISSECTOR; FEMALE; GENE MUTATION; HAZARD RATIO; HEMIHEPATECTOMY; HUMAN; INTRAOPERATIVE PERIOD; KAPLAN MEIER METHOD; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MUTATIONAL ANALYSIS; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SCALPEL; SEGMENTECTOMY; SURGICAL ANATOMY; TUMOR ABLATION; VESSEL SEALING SYSTEM; WEDGE RESECTION; WILD TYPE; COLORECTAL TUMOR; GENETICS; LIVER NEOPLASMS; MORTALITY; MUTATION; PATHOLOGY; PROCEDURES; RECURRENT DISEASE; SECONDARY; TREATMENT OUTCOME;

BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MUTATION; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS P21(RAS); RECURRENCE; TREATMENT OUTCOME;

EID: 85021443290     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000002367     Document Type: Article

References (31)

1. Jones RP, Kokudo N, Folprecht G, et al. Colorectal liver metastases: a critical review of state of the art. Liver Cancer. 2016;6:66-71.
2. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-825. discussion 825-817.
3. de Ridder JA, van der Stok EP, Mekenkamp LJ, et al. Management of liver metastases in colorectal cancer patients: a retrospective case-control study of systemic therapy versus liver resection. Eur J Cancer. 2016;59:13-21.
4. Kopetz S, Chang GJ, Overman MJ, et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol. 2009;27:3677-3683.
5. Lintoiu-Ursut B, Tulin A, Constantinoiu S. Recurrence after hepatic resection in colorectal cancer liver metastasis-Review article. J Med Life. 2015;12-14.
6. Park MS, Yi NJ, Son SY, et al. Histopathologic factors affecting tumor recurrence after hepatic resection in colorectal liver metastases. Ann Surg Treat Res. 2014;87:14-21.
7. Vigano L, Capussotti L, De Rosa G, et al. Liver resection for colorectal metastases after chemotherapy: impact of chemotherapy-related liver injuries, pathological tumor response, and micrometastases on long-term survival. Ann Surg. 2013;258:731-740. discussion 741-732.
8. Yasui K, Shimizu Y. Surgical treatment for metastatic malignancies. Anatomical resection of liver metastasis: indications and outcomes. Int J Clin Oncol. 2005;10:86-96.
9. Shirai Y,Wakai T, Ohtani T, et al. Colorectal carcinoma metastases to the liver. Does primary tumor location affect its lobar distribution? Cancer. 1996;77: 2213-2216.
10. Bockhorn M, Sotiropoulos G, Neuhaus J, et al. Prognostic impact of intrahepatic lymphatic and microvascular involvement in cases of colorectal liver metastases. Int J Colorectal Dis. 2009;24:845-850.
11. Shindoh J, Makuuchi M, Matsuyama Y, et al. Complete removal of the tumorbearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma. J Hepatol. 2016;64:594-600.
12. DeMatteo RP, Palese C, Jarnagin WR, et al. Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg. 2000;4:178-184.
13. Guzzetti E, Pulitano C, Catena M, et al. Impact of type of liver resection on the outcome of colorectal liver metastases: a case-matched analysis. J Surg Oncol. 2008;97:503-507.
14. Kokudo N, Tada K, Seki M, et al. Anatomical major resection versus nonanatomical limited resection for liver metastases from colorectal carcinoma. Am J Surg. 2001;181:153-159.
15. Zorzi D, Mullen JT, Abdalla EK, et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. J Gastrointest Surg. 2006;10:86-94.
16. Lipsyc M, Yaeger R. Impact of somatic mutations on patterns of metastasis in colorectal cancer. J Gastrointest Oncol. 2015;6:645-649.
17. Couinaud C, Delmas A, Patel J. Le foie: Etudes anatomiques et chirurgicales. Paris: Masson & Cie; 1957.
18. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12:351-355.
19. Spolverato G, Pawlik TM. Liver-directed therapies: surgical approaches, alone and in combination with other interventions. Am Soc Clin Oncol Educ Book. 2014;101-110.
20. Aragon RJ, Solomon NL. Techniques of hepatic resection. J Gastrointest Oncol. 2012;3:28-40.
21. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205-213.
22. Margonis GA, Kim Y, Sasaki K, et al. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Cancer. 2016;122:2698-2707.
23. Inoue Y, Hayashi M, Komeda K, et al. Resection margin with anatomic or nonanatomic hepatectomy for liver metastasis from colorectal cancer. J Gastrointest Surg. 2012;16:1171-1180.
24. Matsumura M, Mise Y, Saiura A, et al. Parenchymal-sparing hepatectomy does not increase intrahepatic recurrence in patients with advanced colorectal liver metastases. Ann Surg Oncol. 2016;23:3718-3726.
25. Mise Y, Aloia TA, Brudvik KW, et al. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann Surg. 2016;263:146-152.
26. Finch RJ,Malik HZ, Hamady ZZ, et al. Effect of type of resection on outcome of hepatic resection for colorectal metastases. Br J Surg. 2007;94:1242-1248.
27. Lalmahomed ZS, Ayez N, van der Pool AE, et al. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome? World J Surg. 2011;35:656-661.
28. Margonis GA, Sasaki K, Andreatos N, et al. KRAS mutation status dictates optimal surgical margin width in patients undergoing resection of colorectal liver metastases. Ann Surg Oncol. 2017;24:264-271.
29. Margonis GA, Sasaki K, Kim Y, et al. Tumor biology rather than surgical technique dictates prognosis in colorectal cancer liver metastases. J Gastrointest Surg. 2016;20:1821-1829.
30. Tang H, Li B, Zhang H, et al. Comparison of anatomical and nonanatomical hepatectomy for colorectal liver metastasis: a meta-analysis of 5207 patients. Sci Rep. 2016;6:32304.
31. Rekhtman N, Ang DC, Riely GJ, et al. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol. 2013;26:1307-1319.